1.Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2.
Xiang-Yang LI ; Yong-Nian LIU ; Yong-Ping LI ; Jun-Bo ZHU ; Xing-Chen YAO ; Yong-Fang LI ; Mei YANG ; Ming YUAN ; Xue-Ru FAN ; Yue-Miao YIN
Acta Pharmaceutica Sinica 2014;49(2):267-272
To study the effect of Tibetan medicine Zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2, three different doses (1.2, 3.8 and 12 mg x kg(-1)) of Zuotai were administrated orally to rats once a day or once daily for twelve days, separately. Rats were administrated orally caffeine (CF) on the second day after Zuotai administration, and the urine concentration of CF metabolite 5-acetylamino-6-formylamino-3-methyl-uracil (AFMU), 1-methyluric acid (1U), 1-methylxanthine (1X), 1, 7-dimethylxanthine (17U) at 5 h after study drug administration was determined by RP-HPLC. The activity of CYP1A2 and NAT2 was evaluated by the ratio of metabolites (AFMU+1X+1U)/17U and the ratio of AFMU/(AFMU+1X+1U), respectively. The protein and mRNA expression of CYP1A2 and NAT2 were determined by ELISA and RT-PCR method, respectively. After single administration of Zuotai 3.8 mg x kg(-1) and repeated administration of Zuotai 3.8 and 12 mg x kg(-1), the activity of CYP1A2 and NAT2 decreased significantly compared with control group and there was no significant difference between other dose group and control group. The protein expression of CYP1A2 was significant lower than that in control group after repeated administration of Zuotai 12 mg x kg(-1), and the mRNA expression of CYP1A2 decreased significantly compared with that of control group after single administration of Zuotai 3.8 mg x kg(-1) and repeated admistration of Zuotai 12 mg x kg(-1), separately. The protein expression of NAT2 decreased significantly compared with that of control group after single and repeated administration of Zuotai 3.8 mg x kg(-1), respectively, and the mRNA expression of CYP1A2 decreased significantly compared with control group after single administration of Zuotai 3.8 mg x kg(-1). This study found that Tibetan medicine Zuotai had significant effect on the activity, protein and mRNA expression of CYP1A2 and NAT2.
Administration, Oral
;
Animals
;
Arylamine N-Acetyltransferase
;
genetics
;
metabolism
;
Caffeine
;
metabolism
;
urine
;
Cytochrome P-450 CYP1A2
;
genetics
;
metabolism
;
Dose-Response Relationship, Drug
;
Drugs, Chinese Herbal
;
administration & dosage
;
pharmacology
;
Female
;
Male
;
Medicine, Tibetan Traditional
;
RNA, Messenger
;
metabolism
;
Rats
;
Rats, Sprague-Dawley
;
Theophylline
;
urine
;
Uracil
;
analogs & derivatives
;
urine
;
Uric Acid
;
analogs & derivatives
;
urine
;
Xanthines
;
urine
2.Clinical study on moxibustion for treatment of abnormal blood lipids.
Jian-Ping LI ; Yong-Nian YAO ; Pei-Da HE ; Xia-Man GAN ; Fang-Ling FAN
Chinese Acupuncture & Moxibustion 2005;25(11):825-827
OBJECTIVETo observe clinical therapeutic effect of moxibustion on abnormal blood lipids.
METHODSThe patients who did not take the medicine for regulating blood lipids and had still abnormal blood lipids after diet therapy for 3 months, were divided into 4 groups according to different types of abnormal blood lipids. Forty cases selected in each group were again divided randomly into a treatment group and a control group. The treatment group were treated with moxibustion at Shousanli (LI 10), Zusanli (ST 36) and Shenque (CV 3) on the basis of diet therapy, and the control group only with the diet therapy. Their therapeutic effects were observed and compared after treatment of 90 days.
RESULTSThere were significant differences between the treatment group and the control group in various groups of different types of abnormal blood lipids (P < 0.05).
CONCLUSIONMoxibustion at Shousanli (LI 10), Zusanli (ST 36) and Shenque (CV 3) has a better therapeutic effect on abnormal blood lipids.
Acupuncture Points ; Biomedical Research ; Humans ; Lipids ; blood ; Medicine, Chinese Traditional ; Moxibustion
3.Analysis of expressed sequence tags (EST) from Panax quinquefolium root.
Shi-Lin CHEN ; Yong-Qiao SUN ; Jing-Yuan SONG ; Ying LI ; Chen-Ji LI ; Song-Nian HU ; Xi-Wen LI ; Hui YAO ; Xiao-Wei ZHANG
Acta Pharmaceutica Sinica 2008;43(6):657-663
To investigate the profile of gene expression in American ginseng (Panax quinquefolium L.) and discover its functional genes, for the first time, expressed sequence tags (EST) library of four-year-old American ginseng roots has been established. According to BLAST and Gene Ontology analysis, eleven genes, encoding cytochrome P450, glucosyltransferase, farnesyltransferase and cyclase family protein, are found to be associated with ginsenosides biosynthesis. Six other genes are obtained encoding auxin-regulated protein, auxin response factor 4 and auxin-repressed protein in the roots of American ginseng. In addition, thirteen expressed transcripts are stress-connected proteins and twelve expressed other transcripts are closely related to plant defense in four-year-old American ginseng roots. Furthermore, 62 genes no hit in BLAST and in Interproscan may be new genes. These results indicate EST is an useful tool for research on functional genomics of P. quinquefolium and it can be applied to the molecular modification of the ginsenosides biosynthetic pathway ultimately for improving the quality of American ginseng germplasm.
DNA, Plant
;
genetics
;
Expressed Sequence Tags
;
Gene Expression Profiling
;
Gene Library
;
Genes, Plant
;
Ginsenosides
;
biosynthesis
;
Panax
;
genetics
;
Plant Roots
;
genetics
;
Plants, Medicinal
;
genetics
4. Sudan black B reducing the intestinal autofluorescence of rats and its application in immunofluorescence
Yong LI ; Li ZHOU ; Yang ZHANG ; Feng-Ge SHEN ; Zhi-Yong WANG ; Zhen LIU ; Nian YAO
Acta Anatomica Sinica 2020;51(3):450-455
Objective To develop a feasible method to reduce the rat intestinal autofluorescence (AF). Methods Five rats were sacrificed. After cryostat section, intestinal AF was investigated by immunofluorescence (IF) before and after Sudan black B (SBB) treatment. Results The AF within the different rat intestinal segments was easily detected in both FITC- and TRITC- channel spectrum, which was not affected by serum blocking. After 0. 3% SBB treatment for 10 minutes, a significant reduction of AF was observed in the rat intestinal tissue. Moreover, the SBB treatment did not affect the expression of CD45 in the rat intestine detected by IF staining, but reduced the AF remarkedly. Conclusion The AF in rat intestinal frozen section can be effectively reduced with 0. 3% SBB treatment for 10 minutes.
5.Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study.
Ying ZHENG ; Nian-Song WANG ; Yu-Ning LIU ; Li-Qun HE ; Gui-Hua JIAN ; Xu-Sheng LIU ; Zhao-Hui NI ; Xiao-Hong CHENG ; Hong-Li LIN ; Wen-Hua ZHOU ; Ya-Ping WANG ; Jing-Ai FANG ; Ya-Ni HE ; Hong-Tao YANG ; Li-Juan ZHAO ; Han-Lu DING ; Li-Hua WANG ; Ren-Huan YU ; Wen-Ge LI ; Zhi-Ming YE ; Wang GUO ; Yong-Li ZHAN ; Hui-Juan MAO ; Zhao HU ; Chen YAO ; Guang-Yan CAI ; Xiang-Mei CHEN
Chinese journal of integrative medicine 2019;25(3):168-174
OBJECTIVE:
To follow up the participants of the randomized clinical trial "Efficacy and Safety of Niaoduqing Particles () for Delaying Moderate-to-Severe Renal Dysfunction", and assess the long-term effects of Niaoduqing Particles on delaying the progression of renal dysfunction.
METHODS:
Participants, who had previously been randomly assigned to receive Niaoduqing Particles or placebo for 24 weeks (146 cases in each group), were invited to follow-up and all were administered Niaoduqing Particles 5 g thrice daily and 10 g before bedtime for 24 weeks. The primary endpoints were changes in baseline serum creatinine (Scr) and estimated glomerular filtration rate (eGFR) after completion of the open-label treatment period.
RESULTS:
After the double-blind period, the median (interquartile range) changes in Scr were 1.1 (-13.0-24.1) and 11.7 (-2.6-42.9) μmol/L for the Niaoduqing Particle and placebo groups, respectively (P=0.008), and the median changes in eGFRs were-0.2 (-4.3-2.7) and-2.21 (-5.7-0.8) mL•min•1.73 m, respectively (P=0.016). There were significant differences in the double-blind period changes in renal function between groups. After the open-label period, the median changes in Scr were 9.0 (-10.0-41.9) and 17.5 (-6.0-50.0) μmol/L for the Niaoduqing Particle and placebo groups according to baseline grouping, respectively (P=0.214), and the median changes in eGFRs were-2.3 (-6.4-1.9) and-3.7 (-7.5-1.1) mL•min•1.73 m, respectively (P=0.134). There were no statistical differences in the open-label period changes in renal function between groups. The eGFR reduction of participants who accepted Niaoduqing Particle treatment for 48 weeks was projected to 2.5 mL•min•1.73 m per year.
CONCLUSION
Niaoduqing Particles appear to have long-term efficacy for patients with moderate-to-severe renal dysfunction. Although there was no statistical difference, the early use of Niaoduqing Paticles seems to ameliorate the worsening of renal function. (Trial registration No. ChiCTR-TRC-12002448).
Adult
;
Disease Progression
;
Double-Blind Method
;
Drugs, Chinese Herbal
;
therapeutic use
;
Female
;
Follow-Up Studies
;
Glomerular Filtration Rate
;
drug effects
;
Humans
;
Kidney Diseases
;
drug therapy
;
physiopathology
;
Male
;
Middle Aged
;
Outcome Assessment (Health Care)
6.Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules.
Bo-Hua YAN ; Zhi-Wei JIANG ; Jie-Ping ZENG ; Jian-Yuan TANG ; Hong DING ; Jie-Lai XIA ; Shao-Rong QIN ; Si-Cen JIN ; Yun LU ; Na ZHANG ; Zhi-Hong WANG ; Hai-Yan LI ; Xiao-Ya SANG ; Li-Na WU ; Shi-Yun TANG ; Yan LI ; Meng-Yao TAO ; Qiao-Ling WANG ; Jun-Dong WANG ; Hong-Yan XIE ; Qi-Yuan CHEN ; Sheng-Wen YANG ; Nian-Shuang HU ; Jian-Qiong YANG ; Xiao-Xia BAO ; Qiong ZHANG ; Xiao-Li YANG ; Chang-Yong JIANG ; Hong-Yan LUO ; Zheng-Hua CAI ; Shu-Guang YU
China Journal of Chinese Materia Medica 2020;45(13):2993-3000
To scientifically evaluate the intervention effect of Chinese medicine preventive administration(combined use of Huo-xiang Zhengqi Oral Liquid and Jinhao Jiere Granules) on community population in the case of coronavirus disease 2019(COVID-19), a large cohort, prospective, randomized, and parallel-controlled clinical study was conducted. Total 22 065 subjects were included and randomly divided into 2 groups. The non-intervention group was given health guidance only, while the traditional Chinese medicine(TCM) intervention group was given two coordinated TCM in addition to health guidance. The medical instructions were as follows. Huoxiang Zhengqi Oral Liquid: oral before meals, 10 mL/time, 2 times/day, a course of 5 days. Jinhao Jiere Granules: dissolve in boiling water and take after meals, 8 g/time, 2 times/day, a course of 5 days, followed up for 14 days, respectively. The study found that with the intake of medication, the incidence rate of TCM intervention group was basically maintained at a low and continuous stable level(0.01%-0.02%), while the non-intervention group showed an overall trend of continuous growth(0.02%-0.18%) from 3 to 14 days. No suspected or confirmed COVID-19 case occurred in either group. There were 2 cases of colds in the TCM intervention group and 26 cases in the non-intervention group. The incidence of colds in the TCM intervention group was significantly lower(P<0.05) than that in the non-intervention group. In the population of 16-60 years old, the incidence rate of non-intervention and intervention groups were 0.01% and 0.25%, respectively. The difference of colds incidence between the two groups was statistically significant(P<0.05). In the population older than 60 years old, they were 0.04% and 0.21%, respectively. The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference. The protection rate of TCM for the whole population was 91.8%, especially for the population of age 16-60(95.0%). It was suggested that TCM intervention(combined use of Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules) could effectively protect community residents against respiratory diseases, such as colds, which was worthy of promotion in the community. In addition, in terms of safety, the incidence of adverse events and adverse reactions in the TCM intervention group was relatively low, which was basically consistent with the drug instructions.
Adolescent
;
Adult
;
Betacoronavirus
;
Coronavirus Infections
;
drug therapy
;
Drugs, Chinese Herbal
;
Humans
;
Medicine, Chinese Traditional
;
Middle Aged
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
Prospective Studies
;
Young Adult
7.Catheter ablation versus medical therapy for atrial fibrillation with prior stroke history: a prospective propensity score-matched cohort study.
Wen-Li DAI ; Zi-Xu ZHAO ; Chao JIANG ; Liu HE ; Ke-Xin YAO ; Yu-Feng WANG ; Ming-Yang GAO ; Yi-Wei LAI ; Jing-Rui ZHANG ; Ming-Xiao LI ; Song ZUO ; Xue-Yuan GUO ; Ri-Bo TANG ; Song-Nan LI ; Chen-Xi JIANG ; Nian LIU ; De-Yong LONG ; Xin DU ; Cai-Hua SANG ; Jian-Zeng DONG ; Chang-Sheng MA
Journal of Geriatric Cardiology 2023;20(10):707-715
BACKGROUND:
Patients with atrial fibrillation (AF) and prior stroke history have a high risk of cardiovascular events despite anticoagulation therapy. It is unclear whether catheter ablation (CA) has further benefits in these patients.
METHODS:
AF patients with a previous history of stroke or systemic embolism (SE) from the prospective Chinese Atrial Fibrillation Registry study between August 2011 and December 2020 were included in the analysis. Patients were matched in a 1:1 ratio to CA or medical treatment (MT) based on propensity score. The primary outcome was a composite of all-cause death or ischemic stroke (IS)/SE.
RESULTS:
During a total of 4.1 ± 2.3 years of follow-up, the primary outcome occurred in 111 patients in the CA group (3.3 per 100 person-years) and in 229 patients in the MT group (5.7 per 100 person-years). The CA group had a lower risk of the primary outcome compared to the MT group [hazard ratio (HR) = 0.59, 95% CI: 0.47-0.74, P < 0.001]. There was a significant decreasing risk of all-cause mortality (HR = 0.43, 95% CI: 0.31-0.61, P < 0.001), IS/SE (HR = 0.73, 95% CI: 0.54-0.97, P = 0.033), cardiovascular mortality (HR = 0.32, 95% CI: 0.19-0.54, P < 0.001) and AF recurrence (HR = 0.33, 95% CI: 0.30-0.37, P < 0.001) in the CA group compared to that in the MT group. Sensitivity analysis generated consistent results when adjusting for time-dependent usage of anticoagulants.
CONCLUSIONS
In AF patients with a prior stroke history, CA was associated with a lower combined risk of all-cause death or IS/SE. Further clinical trials are warranted to confirm the benefits of CA in these patients.